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Introduction
Gout is the most prevalent form of inﬂ  ammatory arthritis 
and is associated with impaired quality of life [1-3]. 
Elevation of serum uric acid (SUA) levels, or hyper  uri-
caemia, is an essential prerequisite for the development 
of gout. As SUA levels rise and the physiological 
saturation threshold for uric acid is exceeded in body 
ﬂ   uids, the formation and deposition of monosodium 
urate (MSU) crystals occurs in and around joints. Clinical 
mani  festations of MSU crystal deposition include acute 
attacks of severe pain and inﬂ  ammation aﬀ  ecting peri-
pheral joints, most commonly the ﬁ  rst  metatarso-
phalangeal (MTP) joint, chronic joint damage, and 
topha  ceous deposits of MSU crystals in the joints and 
skin. Recent epidemiological studies have described 
trends in the prevalence and incidence of gout, and have 
increased our understanding of risk factors for its 
development and the implications of co-morbid disease 
on mortality and cardiovascular morbidity.
Prevalence of gout
Epidemiological evidence from New Zealand, the USA, 
the UK and China suggests that gout is becoming more 
prevalent (Table 1) [4-20]. Th  e  ﬁ  ndings of three similarly-
conducted successive surveys from New Zealand show 
an increase in the prevalence of gout, diagnosed by 
interview and physical examination, in both European 
US and Maori subjects [4-6].
In the USA, the prevalence of gout in a managed-care 
administrative claims database increased from 2.9/1,000 in 
1990 to 5.2/1,000 in 1999 [7], most notably in men aged 
over 75 years. Successive National Health Interview 
Surveys in the USA show an increasing prevalence of self-
reported gout, starting from a low of 4.8/1,000 in 1969, 
increasing steadily to peak at 9.9/1,000 in 1983 to 1985, 
and then decreasing slightly to 8.4/1,000 in 1992 [8,9].
Epidemiological surveys from the UK also suggest that 
gout is becoming more prevalent. Surveys undertaken in 
general practice diagnostic indices reported gout preva-
lence per 1,000 of 2.6 in 1975 [10], 3.4 in 1987 [11], and 
9.5 in 1993 [12]. Subsequent studies conducted in the 
UK-General Practice Research Database (UK-GPRD) in 
1999 [13] and the IMS Disease Analyzer from 2000 to 
2005 [14] both found the prevalence of gout to be 1.4%. A 
further UK study undertaken at the Royal College of 
General Practitioners Weekly Returns Service between 
2001 and 2007 reports a lower annual prevalence of 
primary care gout consultation ranging from 4.2/1,000 in 
2002 to 4.9/1,000 in both 2003 and 2006, although there 
was a suggestion of a slight increase in prevalence over 
the study period [15].
Finally, successive random population surveys under-
taken in the city of Qingdao, China report an increase in 
gout prevalence from 3.6/1,000 in 2002 [16] to 5.3/1,000 
in 2004 [17].
Several studies have demonstrated suboptimal manage-
ment of gout in primary care [21-23], which may 
contribute to the rising prevalence of clinically signiﬁ  cant 
symptomatic gout. It should also be noted that the 
diagnosis of gout in these studies was based upon clinical 
assessment, patient self-report, general practice 
diagnosis, medical record/database review, or fulﬁ  lment 
of the 1977 American Rheumatism Association preli-
minary criteria for the acute arthritis of primary gout 
[24] (Table 1) – rather than on microscopic identiﬁ  cation 
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[25]. Clinical diagnosis has been shown to have poor 
sensitivity and speciﬁ   city compared with MSU crystal 
identiﬁ  cation [26,27], and hence such methods risk over-
ascertainment of gout cases.
Incidence of gout
Several studies have examined the incidence of gout. Th  e 
John Hopkins Precursors Study followed 1,216 male 
medical students for a median of 29 years, identifying 60 
cases of incident gout (incidence 1.73 per 1,000 patient-
years) [28]. In the Framingham Heart Study, which 
followed 5,209 people for a median of 28 years, 104 
incident cases of gout in women and 200 cases in men 
were documented [29] – giving an incidence of gout per 
1,000 person-years of 1.4 in women and 4.0 in men.
Data from two general practice consultation databases 
show the incidence of gout to be stable in the UK. Th  e 
earlier study, undertaken in the UK-GPRD between 1990 
and 1999, found gout incidence per 10,000 patient-years 
Table 1. Increasing prevalence of gout: epidemiological data from New Zealand, the USA, the UK and China
Study  Survey date  Study population  Case defi  nition  Prevalence
New Zealand       
Lennane and colleagues [4]  1958  Random community sample  Personal interview and examination  European 3/1,000, 
       Maori  27/1,000
Prior and Rose [5]  1966  Random community sample  Personal interview and examination  European 9/1,000, 
       Maori  60/1,000
Klemp and colleagues [6]  1992  Random community sample  Personal interview and examination;   European 29/1,000,
      1977 ARA criteria  Maori 64/1,000
USA     
Wallace and colleagues [7]  1990  Medical claims database  Claims with gout diagnosis or urate-lowering   2.9/1,000
     drugs
 1999      5.2/1,000
Lawrence and colleagues [8,9]  1969  National Health Interview Surveys  Self-reported gout  4.8/1,000
 1976      7.8/1,000
 1980      8.3/1,000
  1983 to 1985      9.9/1,000
 1988      8.5/1,000
 1992      8.4/1,000
UK      
Currie [10]  1975  GP records  GP diagnosis  2.6/1,000
Steven [11]  1987  GP records (Scotland)  Specialist review of clinical records  3.4/1,000
Harris and colleagues [12]  1993  GP records (England)  GP diagnosis  9.5/1,000
Mikuls and colleagues [13]  1999  UK-GPRD  GP diagnosis  14/1,000
Annemans and colleagues [14]  2000 to 2005  IMS Disease Analyzer  GP diagnosis  14/1,000
Elliot and colleagues [15]   2001  RCGP Weekly Returns Service  GP diagnosis  4.3/1,000
 2003      4.9/1,000
 2005      4.8/1,000
 2007      4.7/1,000
China      
Nan and colleagues [16]  2002  Random community sample  Self-report, confi  rmed in medical records  3.6/1,000
Miao and colleagues [17]  2004  Random community sample  Questionnaire, physical examination  5.3/1,000
      1977 ARA criteria
Taiwan
Chou and colleagues [18]  Not stated  Random community sample  Questionnaire, physical examination.   Rural 1.6/1,000. 
      Hyperuricaemia/synovial fl  uid analysis  suburban 6.7/1,000, 
       urban  6.7/1,000
Chang and colleagues [19]  1993 to 1995  Random community sample  Personal interview, 1977 ARA criteria  Aborigine 91/1,000, 
       non-Aborigine  3/1,000
Lin and colleagues [20]  1993 to 1996  Nutrition and Health Survey  Personal interview, physical examination  34/1,000
ARA, American Rheumatism Association; GP, general practitioner; RCGP, Royal College of General Practitioners; UK-GPRD, UK General Practice Research Database.
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cases in 1994, before stabilising at 13.1 cases in 1999 [13]. 
In a later study, undertaken at the Royal College of 
General Practitioners Weekly Returns Service between 
1994 and 2007, the mean annual incidence was 18.6 per 
10,000 population [15]. In both studies, gout incidence 
was higher in men than in women and increased with 
age. In contrast, successive surveys from the USA 
undertaken as part of the Rochester Epidemiology 
Project computerised medical records system found the 
age-adjusted and sex-adjusted annual incidence of acute 
gout to increase from 45.0/100,000 in 1977/78 to 
62.3/100,000 in 1995/96 [30]. Th  e largest increase in 
incidence occurred in elderly men and in primary gout 
(that is, no history of diuretic use).
Risk factors for the development of gout
Hyperuricaemia
Hyperuricaemia is considered the most important risk 
factor for the development of gout. In a community-
based, cross-sectional Taiwanese study of 3,185 adults 
aged over 30 years, the odds ratio (OR) for prevalent gout 
was 3.65 (95% conﬁ   dence interval (CI) = 2.72, 5.09) 
between men with and without hyperuricaemia (SUA 
≥7.0 mg/dl) [31]. Th   e 5-year cumulative incidence of gout 
was 18.8% in 223 men who had asymptomatic hyper-
uricaemia at baseline [32]. A dose-dependent eﬀ  ect on 
the 5-year cumulative incidence of gout was seen with 
increasing SUA level (SUA 7.0 to 7.9 mg/dl, 10.8%; SUA 
8.0 to 8.9 mg/dl, 27.7%; SUA ≥9.0 mg/dl, 61.1%) [32]. Th  e 
Normative Aging Study followed 2,046 male veterans 
aged 21 to 81 years over a period of 15 years, identifying 
84 new cases of acute gouty arthritis [33]. Th  e 5-year 
cumulative incidence of gout increased as SUA increased 
(Figure 1). In the Framingham Heart Study, the risk of 
developing gout increased with increasing SUA level in 
both men and women (Figure 2) [29]. Gout incidence 
rates increased exponentially with increasing SUA levels 
in both studies (Table 2) [29,33].
Genetic factors
Familial clustering is often evident in common primary 
gout, and twin studies show high heritability for both 
uric acid renal clearance (60%) and uric acid:creatinine 
ratio (87%) [34,35]. Th  e usual mechanism of hyper-
uricaemia in primary gout relates predominantly to 
relative ineﬃ       ci  ency in excretion rather than over-
production. It is esti  mated that approximately 30% of 
the body’s uric acid is excreted into the intestine by ill-
deﬁ   ned mechanisms, and is broken down by colonic 
bacteria (which possess uricase) to allantoin. Th  e  kidney 
excretes the majority (70%) of uric acid excretion, 
however, and renal mecha  nisms appear key to the 
understanding of hyperuri  caemia. Recent interest has 
therefore particularly focused on genes regulating renal 
urate transport [36].
Th   e SLC22A12 gene codes for human urate transporter 1 
(URAT1), a member of the organic anion transporter 
family that, together with other recently identiﬁ  ed trans-
porters, is important in controlling reabsorption of uric 
acid from the proximal renal tubules. URAT1 is the site 
of action for many drugs and ions that inﬂ  uence SUA. 
For example, lactate, nicotinate and pyrazinoate act as a 
substrate for URAT1 and increase reabsorption of uric 
acid (causing an increase in SUA), whereas benzbro-
marone, probenecid and losartan inhibit URAT1 to cause 
Figure 1. Incidence of gout according to serum uric acid level. 
Five-year cumulative incidence of gout according to serum uric acid 
level in men in the Normative Aging Study [33].
Figure 2. Risk of developing gout according to serum uric 
acid level. Relative risk of developing gout according to serum 
uric acid level in men and women in the Framingham Heart Study 
[29]. Referent group: serum uric acid <5.0 mg/dl. *Adjusted for age, 
education, body mass index, alcohol consumption, hypertension, 
diuretic use, blood glucose level, blood cholesterol level, and 
menopausal status.
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morphism of this gene has been associated with relative 
under-excretion of uric acid and hyperuricaemia in 
German Caucasians [38], and inactivating mutations of 
URAT1 have been shown in Japanese patients to cause 
marked hypouricaemia [39].
Th   e glucose and fructose transporter SLC2A9 (GLUT9) 
is another urate transporter in proximal renal tubules 
[40], and polymorphisms of this gene have been asso-
ciated with increased SUA [41,42] and with self-reported 
gout [43]. Th  e association between polymorphisms in 
SLC2A9 and both high SUA levels and risk of gout was 
conﬁ  rmed in a genome-wide association study of three 
large cohorts [44]. Th   is study also identiﬁ  ed two further 
gene associations in ABCG2 (a urate eﬄ   ux transporter in 
proximal collecting duct cells) and SLC17A3 (encoding 
NPT4 – a proximal tubule sodium/phosphate co-trans-
porter), allowing development of a genetic score to 
predict risk of gout. Polymorphisms in the SLC17A1 
gene, which codes for NPT1, a sodium-dependent phos-
phate co-transporter, have also been shown to associate 
with gout [45]. Two recent meta-analyses of genome-
wide association studies have conﬁ  rmed these associa-
tions, although except for SCL2A9, which may account 
for up to 5% of variance of uric acid levels, the other 
genetic associations each appear to account for less than 
1% of variance [46,47].
Two other reported genetic associations with hyperuri-
caemia are of special interest. Firstly, the 64Arg variant of 
the β3-adrenergic receptor (ADRB3) gene – which may 
also induce insulin resistance through reduced lipolysis 
and increase in adipocytes, thus possibly providing an 
explanation for the link between these facets of the 
metabolic syndrome [48]. Secondly, the 677T allele of the 
methylene tetrahydrofolate reductase (MTHFR) gene – 
which may facilitate availability of methylene tetrahydro-
folate for de novo purine synthesis [49]. Single gene 
mutations that cause hyperuricaemia and gout are very 
rare, but examples of these include, uromodulin, renin, 
the aldolase B (ALDOB) gene and hypoxanthine guanine 
phosphoribosylpyrophosphate – the cause of Lesch–
Nyhan syndrome [49].
Given its high heritability, further genetic studies are 
warranted. However, future studies require careful pheno-
typic characterisation. Th  ere should be clear distinction 
between studies examining the genetics of hyperuri-
caemia, which probably are best judged at a young age 
before development of co-morbidities, drug intake and 
age-related renal impairment, and those linking genetic 
associations with crystal deposition and gout, since 
diﬀ  erent associations may emerge.
Dietary factors
An association between gout and dietary factors has been 
recognised for centuries. Only recently, however, has this 
been conﬁ  rmed in large, well-designed epidemiological 
studies (Table 3). Th  e Health Professionals Follow-up 
Study (HPFS) was a large, prospective cohort study that 
followed 51,529 male health professionals, documenting 
757 incident cases of gout over a 12-year period. Gout 
cases were required to meet the 1977 American Rheuma-
tism Association preliminary criteria [24]. Dietary intake 
was assessed using a semiquantitative food frequency 
questionnaire administered at baseline and at 4-year and 
8-year follow-up [50]. Dietary consumption of meat and 
seafood was associated with an increased risk of gout, 
whereas consumption of dairy products appeared to be 
protective [51]. After adjustment for age, body mass 
index (BMI), diuretic use, hypertension, renal failure, 
alcohol intake, and other dietary factors, the multivariate 
relative risk (RR) of developing gout was 1.41 among men 
in the highest quintile of total meat intake compared with 
those in the lowest quintile (95% CI = 1.07, 1.86). Th  e 
multivariate RR of developing gout in those among the 
highest quintile of seafood consumption versus the lowest 
quintile was 1.51 (95% CI = 1.17, 1.95). Consumption of 
purine-rich vegetables was not associated with the 
develop  ment of gout. Th   e risk of developing gout 
Table 2. Incidence rate of gout in relation to serum uric acid levels
    Incidence rate of gout per 1,000 person-years
Serum uric acid level  Normative Aging Study (men)   Framingham Heart Study (men)   Framingham Heart Study (women) 
(mg/dl) [33]  [29]  [29]
<5.0   0.8  0.8
5.0 to 5.9  0.8a 3.4  2.5
6.0 to 6.9  0.9  8.0  4.2
7.0 to 7.9  4.1  17.8  13.1
8.0 to 8.9  8.4  32.9b 27.3b
9.0 to 9.9  43.2   
≥10.0 70.2   
aIncidence rate for serum uric acid <6.0 mg/dl. bIncidence rate for serum uric acid ≥8.0 mg/dl.
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(highest versus lowest quintile; multivariate RR = 0.56, 95% 
CI = 0.42, 0.74). Th   is association was seen for low-fat dairy 
products (multivariate RR = 0.58, 95% CI = 0.45, 0.77) but 
not for high-fat dairy products (highest versus lowest 
quintile; multivariate RR = 1.00, 95% CI = 0.77, 1.29).
In a subsequent HPFS study, the same authors 
examined the relationship between coﬀ  ee consumption 
and the risk of developing gout [52]. Consumption of six 
or more cups of coﬀ  ee per day appeared to be protective 
against the development of gout (multivariate RR = 0.41, 
95% CI = 0.19, 0.88) compared with no coﬀ  ee consump-
tion. Although the risk of developing gout was not signi-
ﬁ    cantly decreased in those drinking four or more cups of 
decaﬀ  einated coﬀ  ee per day compared with no con  sump-
tion (multivariate RR = 0.73, 95% CI = 0.46, 1.17), a 
signiﬁ  cant protective eﬀ  ect was seen in those drinking 
smaller amounts of decaﬀ  einated coﬀ  ee and a statistically 
signiﬁ  cant trend was seen across the groups. Tea con-
sumption and total caﬀ  eine intake were not associated 
with development of gout. Subsequently, the authors 
explored the relationship between intake of sugar-
sweetened soft drinks and fructose and the risk of incident 
gout [53]. Fructose increases degradation of purine 
nucleo  tides, which act as a substrate for uric acid produc-
tion [54]. Consumption of two or more sugar-sweetened 
soft drinks per day was a risk factor for the development of 
gout (multivariate RR = 1.85, 95% CI = 1.08, 3.16) 
compared with less than one per month [53]. Diet soft 
drinks did not appear to confer risk of developing gout. 
Increasing total fructose intake, how  ever, increased the 
risk of incident gout (highest versus lowest quintile; 
multivariate RR = 1.81, 95% CI = 1.31, 2.50).
Most recently, the authors have examined the risk of 
developing gout with vitamin C consumption using 
20-year follow-up data from the HPFS (including 1,317 
incident gout cases) [55]. Higher total vitamin C con-
sump  tion appeared to be protective against the develop-
ment of gout. Th   e multivariate RR of developing gout was 
0.55 (95% CI = 0.38, 0.80) in those consuming >1,500 mg 
dietary vitamin C per day compared with those consum-
ing <250 mg/day.
Local variation in the prevalence of gout has been 
suggested to be inﬂ  uenced by dietary habits. A cross-
sectional study of 5,003 adults found the prevalence of 
gout across ﬁ  ve coastal cities in the Shandong province of 
China to range from 0.50% to 2.55% [17]. Consumption 
of meat and seafood was signiﬁ  cantly higher in the city of 
Yantai where gout prevalence was the highest, compared 
with the city of Dongying that had the lowest prevalence 
of gout – raising the possibility that variations in the 
prevalence of gout might be directly attributable to 
lifestyle factors [56].
Alcohol consumption
Similar to dietary factors, an association between gout 
and excess alcohol consumption has long been recog-
nised. Although it is now thought that the epidemic of 
Table 3. Risk of incident gout in men with diet and alcohol intake: Health Professionals Follow-up Study
Dietary factor  Comparison  Multivariate RR (95% CI)
Total meat intake [51]  Highest versus lowest quintile  1.41 (1.07, 1.86)
Seafood [51]  Highest versus lowest quintile  1.51 (1.17,1.95)
Vegetable purines [51]  Highest versus lowest quintile  0.96 (0.74, 1.24)
Dairy products [51]  Highest versus lowest quintile  0.56 (0.42, 0.74)
Low-fat dairy products [51]  Highest versus lowest quintile  0.58 (0.45, 0.76)
High-fat dairy products [51]  Highest versus lowest quintile  1.00 (0.77, 1.29)
Coff  ee [52]  ≥6 cups per day versus none  0.41 (0.19, 0.88)
Decaff  einated coff  ee [52]  ≥4 cups per day versus none  0.73 (0.46, 1.17)
Tea [52]  ≥4 cups per day versus none  0.82 (0.38, 1.75)
Total caff  eine [52]  Highest versus lowest quintile  0.83 (0.64, 1.08)
Sugar-sweetened soft drinks [53]  ≥2 drinks per day versus none  1.85 (1.08, 3.16)
Diet soft drinks [53]  ≥2 drinks per day versus none  1.12 (0.82, 1.52)
Total fructose [53]  Highest versus lowest quintile  1.81 (1.31, 2.50)
Total vitamin C [55]  ≥1,500 mg versus <250 mg/ day  0.55 (0.38, 0.80)
Total alcohol [58]  ≥50 g per day versus none  2.53 (1.73, 3.70)
Beer [58]  ≥2 drinks per day versus none  2.51 (1.77, 3.55)
Spirits [58]  ≥2 drinks per day versus none  1.60 (1.19, 2.16)
Wine [58]  ≥2 drinks per day versus none  1.05 (0.64, 1.72)
CI, confi  dence interval; RR, relative risk.
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lead poisoning resulting from the high lead content of 
wines and port at this time [57], recent epidemiological 
data support the important relationship between alcohol 
consumption and risk of developing gout today.
In the HPFS, a graded association was observed 
between alcohol intake and the risk of developing gout 
on multivariate analysis (no alcohol intake, RR = 1.00; 0.1 
to 4.9 g/day, RR = 1.09; 5.0 to 9.9 g/day, RR = 1.25; 10.0 to 
14.9 g/day, RR = 1.32; 15.0 to 29.9 g/day, RR = 1.49; 30.0 
to 49.9 g/day, RR = 1.96; ≥50.0 g/day, RR = 2.53) [58]. Th  e 
multivariate RR was 1.17 (95% CI = 1.11, 1.22) per 10 g 
increase in alcohol intake per day. Comparing those who 
drank two or more drinks per day with those who did not 
drink, the risk of developing gout was greatest for beer 
consumption (RR = 2.51, 95% CI = 1.77, 3.55) followed by 
spirits (RR = 1.60, 95% CI = 1.19, 2.16), whereas wine 
consumption conferred no risk (RR = 1.05, 95% CI = 0.64, 
1.72) (Table 3). Th  e multivariate RR per serving per day 
was 1.49 (95% CI = 1.32, 1.70) for beer, 1.15 (95% CI = 1.04, 
1.28) for spirits, and 1.04 (95% CI = 0.88, 1.22) for wine.
Excess alcohol consumption has also been shown to be 
an important risk factor for the development of gout in 
women. In the Framingham Heart Study, alcohol con-
sump  tion was categorised as heavy, moderate and 
abstinent/light [29]. Compared with people whose alcohol 
intake was abstinent/light (0 to 1 ounce per week), the 
multivariate RR of developing gout in the heavy alcohol 
consumption category (≥7 ounces per week) was 3.10 (95% 
CI = 1.69, 5.68) in women and 2.21 (95% CI = 1.56, 3.14) in 
men.
Alcohol consumption has also been shown to trigger 
attacks of acute gout. In an Internet cross-over study of 
321 acute attacks in 197 subjects, a dose-dependent 
relation  ship was found between the number of alcoholic 
drinks consumed in the previous 48 hours and an acute 
attack of gout (seven alcoholic drinks in 48 hours: OR = 
2.5, 95% CI = 1.1, 5.9) [59].
Several mechanisms by which alcohol predisposes to 
hyperuricaemia have been proposed, including reduced 
renal urate excretion via lactic acidosis or lead poisoning, 
increased urate production via ethanol-induced 
accelerated degradation of purine nucleotides or the high 
purine content of beer enhancing substrate provision, 
and poor compliance with urate-lowering therapy [60].
Metabolic syndrome
Gout has an important association with the metabolic 
syndrome. A study undertaken using data from the Th  ird 
National Health and Nutrition Examination Survey, con-
ducted between 1988 and 1994, compared the preva  lence 
of the metabolic syndrome – deﬁ  ned using the revised 
National Cholesterol Education Program Adult Treat-
ment Panel III criteria [61] – between individuals with 
gout and control subjects without gout [61,62]. Amongst 
individuals with gout the prevalence of meta  bolic 
syndrome was 62.8%, compared with 25.4% among those 
without gout (age-adjusted and sex-adjusted OR = 3.05, 
95% CI = 2.01, 4.61).
Other studies have reported the relationship between 
gout and various individual components of the metabolic 
syndrome. In the HPFS, on multivariate analysis, there 
was a clear graded association between increasing BMI 
and the risk of incident gout in men (BMI <21 kg/m2, 
RR = 0.85; BMI 21 to 22.9 kg/m2, RR = 1.00; BMI 23 to 
24.9 kg/m2, RR = 1.31; BMI 25 to 29.9 kg/m2, RR = 1.95; 
BMI 30 to 34.9 kg/m2, RR = 2.33; BMI ≥35 kg/m2, RR = 
2.97) [63]. A similar relationship was seen between 
incident gout and waist:hip ratio. Compared with men 
who had maintained their weight, graded associations 
were also seen between weight gain since study entry and 
increased risk of gout (weight gain ≥30 lbs, multivariate 
RR = 1.72, 95% CI = 1.02, 2.91). Weight loss since study 
entry decreased the risk of gout (weight loss ≥10 lbs, 
multi  variate RR = 0.61, 95% CI = 0.40, 0.92). Th  e 
Framing  ham Heart Study also identiﬁ  ed obesity as a risk 
factor for developing gout [29]. Th  e multivariate RR of 
developing gout was 2.74 (95% CI = 1.65, 4.58) in obese 
women (BMI ≥30 kg/m2) and 2.90 (95% CI = 1.89, 4.44) 
in obese men, compared with those with BMI <25 kg/m2.
Several studies have examined the relationship between 
gout and hypertension. In a case–control study under-
taken in the UK-GPRD that compared 56,483 gout cases 
with 150,867 controls subjects with osteoarthritis (OA), 
the age-adjusted and sex-adjusted OR for gout in patients 
with hypertension was 1.52 (95% CI = 1.48, 1.56) [13]. 
Th  e HPFS and Framingham Heart Study found multi-
variate RRs of incident gout with hypertension of 2.31 
(95% CI = 1.96, 2.72) and 1.59 (95% CI = 1.12, 2.24), 
respec  tively, in men and 1.82 (95% CI = 1.06, 3.14) in 
women [29,63].
Th  e UK-GPRD study found a small but statistically 
signiﬁ  cant association between gout and diabetes mellitus 
(age-adjusted and sex-adjusted OR = 1.11, 95% CI = 1.06, 
1.16) [13]. Interestingly, whereas most epidemiological 
studies concerning gout and components of the 
metabolic syndrome have focused on the risk of incident 
gout in people with individual co-morbid conditions, 
gout itself has been shown to be a risk factor for incident 
type 2 diabetes mellitus in men [64]. A prospective cohort 
study of 11,351 men was nested within the Multiple Risk 
Factor Intervention Trial, a randomised clinical trial of a 
coronary risk reduction programme in men at high risk of 
cardiovascular disease (CVD). After exclusion of men with 
diabetes at baseline, the multivariate RR of incident type 2 
diabetes mellitus was 1.34 (95% CI = 1.09, 1.64) in men 
who self-reported gout at baseline compared with those 
without a history of gout [64].
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Diuretic use is a signiﬁ  cant risk factor for the develop-
ment of gout but this relationship is potentially con-
founded by the indication for diuretic therapy, such as 
hypertension, renal disease and cardiac failure, which 
may also predispose to gout. Diuretic-induced hyper-
uricaemia occurs via inhibition of renal urate excretion at 
the low-aﬃ     nity asymmetric urate transporter, organic 
anion transporter 4 (OAT4) [65]. Diuretics have been 
shown to be a risk factor for incident gout in men in the 
HPFS (RR = 1.77, 95% CI = 1.42, 2.20) [63] and in both 
sexes in the Framingham Heart Study (men RR = 3.41, 
95% CI = 2.38, 4.89; women RR = 2.39, 95% CI = 1.53, 
3.74) [29] after adjustment for multiple confounders, 
including hypertension. An association between diuretic 
use and gout was also seen in the UK-GPRD (OR = 1.72, 
95% CI = 1.67, 1.76, adjusted for age and sex but not 
hypertension) [13]. In contrast, a Dutch case–control 
study did not ﬁ  nd an association between incident gout 
and prior diuretic use (incidence rate ratio = 0.6, 95% 
CI  = 0.2, 2.0), although the study was small (70 gout 
cases) and several important confounding variables were 
not adjusted for [66]. Diuretic use also predisposes to 
recurrent acute gout. In the Internet cross-over study 
described above, diuretic use in the preceding 48 hours 
was associated with acute attacks of gout (OR = 3.6, 95% 
CI = 1.4, 9.7) [67].
Renal disease
Chronic renal disease is an important risk factor for gout. 
It was associated with gout in both the HPFS (RR = 3.61, 
95% CI = 1.60, 8.14, adjusted for multiple confounders 
including diuretic use) [63] and the UK-GPRD (age-
adjusted and sex-adjusted OR = 4.95, 95% CI = 4.28, 5.72) 
[13]. Gout can be particularly challenging in patients 
with end-stage renal disease or following renal trans-
plantation. A retrospective study of 259,209 patients 
registered in the US Renal Data System found the 
incidence of gout to be 5.4% in the ﬁ  rst year of dialysis 
and 15.4% in the ﬁ  rst 5 years [68]. In the UK-GPRD, gout 
was associated with both renal transplantation (OR = 
25.13, 95% CI = 12.97, 48.68) and cyclosporin use (OR = 
7.93, 95% CI = 5.97, 10.54), although risk estimates were 
only adjusted for age and sex [13].
Osteoarthritis
Gout shows a striking predilection to aﬀ  ect certain joints, 
most strikingly the ﬁ  rst MTP joint. Although it is not 
known why gout demonstrates such a characteristic 
pattern, the ﬁ  rst MTP joint is also a target joint for OA 
and it has been postulated that MSU crystals may deposit 
more readily in osteoarthritic cartilage [69]. Radiographic 
and clinical studies support the tendency of gout to occur 
at joints already aﬀ  ected by OA. A Polish hospital-based 
study of 262 subjects with gout found the presence of 
gout and radiographic OA to be signiﬁ  cantly correlated 
at the ﬁ  rst MTP joints, tarsal joints and knees [70]. More 
recently, a community-based study of 164 subjects with 
gout found a strong association between sites of acute 
attacks of gout and the presence of clinical OA (multi-
variate OR = 7.94, 95% CI = 6.27, 10.05), especially at the 
ﬁ   rst MTP joints, tarsal joints, knees and ﬁ  nger  distal 
interphalangeal joints [71]. Such cross-sectional asso  cia-
tions cannot diﬀ  erentiate whether OA predisposes to or 
arises from MSU crystal deposition. Th  e association 
between gout and OA at individual joint sites was not 
aﬀ  ected by gout duration [71], however, which does not 
support the latter hypothesis. Nodal OA was no more 
frequent in gout subjects than control subjects without 
gout from the same community [72]. Th  ese ﬁ  ndings 
suggest that OA predisposes to local MSU crystal depo-
sition in individuals with gout, but is not a risk factor for 
gout per se.
Mortality and cardiovascular disease associated 
with gout
As discussed above, there is a strong association between 
gout and co-morbid disease, including traditional cardio-
vascular risk factors. Gout has a well-recognised associa-
tion with CVD, but there has been much debate as to 
whether this risk is independent of traditional cardio-
vascular risk factors (Table 4).
Th   e association between gout and all-cause and cardio-
vascular mortality was examined in men in the HPFS 
[73]. Th  e multivariate RR of death from any cause was 
1.28 (95% CI = 1.15, 1.41) in men with self-reported 
physician-diagnosed gout but no history of CVD at 
baseline, compared with those with neither gout nor 
CVD. Death from both CVD (RR = 1.38, 95% CI = 1.15, 
1.66) and coronary heart disease (CHD) (RR = 1.55, 95% 
CI = 1.24, 1.93) were also more common in those with 
gout. Similar risk estimates were seen when, amongst 
men with pre-existing CHD at baseline, mortality was 
compared between those who had self-reported 
physician-diagnosed gout and those who did not: all-
cause mortality, RR = 1.25 (95% CI = 1.09, 1.45); CVD 
death, RR = 1.26 (95% CI = 1.07, 1.50); and fatal CHD, 
RR = 1.24 (95% CI = 1.04, 1.49). Gout was associated with 
death from any cause (multivariate RR = 1.49, 95% CI = 
1.43, 1.55) and with CVD death (multivariate RR = 1.47, 
95% CI = 1.25, 1.59) in the study of gout in renal disease 
undertaken in the US Renal Data System described above 
[68]. In the Multiple Risk Factor Intervention Trial 
cohort, there was an increased risk of CHD death (hazard 
ratio = 1.35, 95% CI = 1.06, 1.72) in men with self-
reported gout at baseline compared with those without 
no history of gout [74]. However, gout was not associated 
with death from acute myocardial infarction or CVD.
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mortality in men. A further study examined all-cause and 
cardiovascular mortality in 61,527 people of either sex 
identiﬁ  ed from health screening participants attending a 
Taiwanese hospital between 2000 and 2006 [75]. Multi-
variate hazard ratios of all-cause and cardiovascular 
mortality between 1,311 subjects with gout compared 
with 48,021 subjects with normouricaemia were 1.46 
(95% CI = 1.12, 1.91) and 1.97 (95% CI = 1.08, 3.59), 
respectively. Hyperuricaemia per se was not associated 
with mortality.
Several studies have examined the relationship between 
gout and cardiovascular morbidity. A Dutch general 
practice study compared incident CVD (a composite 
outcome of angina, myocardial infarction, heart failure, 
cerebrovascular accident, transient ischaemic attack, and 
peripheral vascular disease) in 170 gout cases and 340 
control subjects without prevalent CVD at baseline [76]. 
Gout was not an independent risk factor for CVD (risk 
ratio = 0.98, 95% CI = 0.65, 1.47), although only a small 
number of potential confounders were accounted for. 
Similarly in the Meharry–Hopkins Study of 1,552 male 
Table 4. Risk of mortality and cardiovascular disease associated with gout
Study Design  Population  Comparison  Multivariate  risk 
estimate (95% CI)
All-cause mortality       
HPFS [73]  Cohort: stratifi  ed by baseline   51,927 male health professionals,   CHD: gout vs. no gout  RR = 1.25 (1.09, 1.45)
  CHD status  40 to 75 years old
      No CHD: gout vs. no gout  RR = 1.28 (1.15, 1.41)
MRFIT [74]  MRFIT RCT participants  9,105 men, 41 to 63 years old  Gout vs. no gout  HR = 1.09 (1.00, 1.19)
CGMH [75]  Cohort: health screening   61,527 men and women,   Gout vs. normouricaemia  HR = 1.46 (1.12, 1.91)
  programme participants  30 to 74 years old
All cardiovascular death    
HPFS [73]  Cohort: stratifi  ed by baseline   51,927 male health professionals,   CHD: gout vs. no gout  RR = 1.26 (1.07, 1.50)
  CHD status  40 to 75 years old
      No CHD: gout vs. no gout  RR = 1.38 (1.15, 1.66)
MRFIT [74]  MRFIT RCT participants  9,105 men, 41 to 63 years old  Gout vs. no gout  HR = 1.21 (0.99, 1.49)
CGMH [75]  Cohort: health screening   61,527 men and women,   Gout vs. normouricaemia  HR = 1.97 (1.08, 3.59)
  programme participants  30 to 74 years old
Fatal CHD      
HPFS [73]  Cohort: stratifi  ed by baseline   51,927 male health professionals,   CHD: gout vs. no gout  RR = 1.24 (1.04, 1.49)
  CHD status  40 to 75 years old
      No CHD: gout vs. no gout  RR = 1.55 (1.24, 1.93)
MRFIT [74]  MRFIT RCT participants  9,105 men, 41 to 63 years old  Gout vs. no gout  HR = 1.35 (1.06, 1.72)
Fatal myocardial infarction     
MRFIT [74]  MRFIT RCT participants  9,105 men, 41 to 63 years old  Gout vs. no gout  HR = 1.35 (0.94, 1.93)
Cardiovascular disease     
Dutch primary care [76]  Follow-up of case–control study   261 men and women  Gout vs. no gout  RR = 0.98 (0.65, 1.47)
 participants
Coronary heart disease     
Framingham Study [78]  Cohort  2,316 men  Gout vs. no gout  RR = 1.6 (1.1, 2.5)
Meharry–Hopkins Study [77]  Cohort  1,552 male physicians  Gout vs. no gout  RR = 0.59 (0.24, 1.46) 
GPRD [13]  Case–control  207,350 men and women  Gout vs. osteoarthritis  OR = 1.75 (1.70, 1.79)
Myocardial infarction     
Framingham Study [78]  Cohort  2,316 men  Gout vs. no gout  RR = 1.5 (0.9, 2.6)
MRFIT [79]  MRFIT RCT participants  12,866 men  Gout vs. no gout  OR= 1.26 (1.14, 1.40)
Angina pectoris       
Framingham Study [78]  Cohort  2,316 men  Gout vs. no gout  RR = 1.8 (1.1, 3.2)
CGMH, Chang Gung Memorial Hospital; CHD, coronary heart disease; CI, confi  dence interval; GPRD, General Practice Research Database; HPFS, Health Professionals 
Follow-up Study; HR, hazard ratio; MRFIT, Multiple Risk Factor Intervention Trial; OR, odds ratio; RCT, randomised controlled trial; RR, relative risk.
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risk factor for CHD over a mean follow-up period of 30 
years (multivariate RR = 0.59, 95% CI = 0.24, 1.46) [77]. 
In contrast, in the Framingham Study, the 2-year age-
adjusted incidence of CHD was 5.8/1,000 in men with 
gout compared with 3.8/1,000 in those without gout 
(multivariate RR = 1.6, 95% CI = 1.1, 1.25) [78]. 
Interestingly, increased risk of CHD was primarily 
attributable to a twofold risk of angina. In the UK-GPRD 
study, an association was observed between gout and 
coronary artery disease (age-adjusted and sex-adjusted 
OR = 1.75, 95% CI = 1.70, 1.79) [13]. Within the Multiple 
Risk Factor Intervention Trial cohort, gout was found to 
be a signiﬁ   cant independent predictor of subsequent 
nonfatal acute myocardial infarction (OR = 1.31, 95% CI 
= 1.24, 1.38) after adjustment for multiple confounding 
variables including co-morbidity and hyperuricaemia 
[79]. An association between gout and coronary heart 
disease was also seen in the UK-GPRD (age-adjusted and 
sex-adjusted OR = 1.75, 95% CI = 1.70, 1.79) [13].
Conclusions
Gout is the most common form of inﬂ  ammatory arthritis, 
and the ﬁ   ndings of several studies suggest that the 
prevalence and incidence of gout has risen in recent 
decades. Numerous risk factors for the development of 
gout in men and women have now been established in 
prospective epidemiological studies, including hyperuri-
caemia, genetic factors, dietary factors, alcohol consump-
tion, metabolic syndrome (including hypertension and 
obesity), diuretic use and renal disease. OA appears to 
predispose to local MSU crystal deposition but is not a 
risk factor for the development of gout per se. Gout 
appears to be an independent risk factor for all-cause 
mortality and CVD mortality and morbidity beyond that 
which would be expected from its strong association with 
traditional co-morbid cardiovascular risk factors.
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